Role of angiotensin II in the evolution of diastolic heart failure

Area of Science:

• Cardiology
• Internal Medicine
• Hypertension Research

Background:

• Diastolic heart failure (HF) constitutes over 50% of all HF cases.
• Prevalence increases with age, from 46% in those <45 years to 59% in those ≥85 years.
• Associated with an annual mortality rate exceeding 10%.

Purpose of the Study:

• To review the diagnosis and pathophysiology of diastolic HF.
• To explore the role of neurohormonal activation in diastolic dysfunction.
• To provide a rationale for therapeutic interventions targeting the renin-angiotensin-aldosterone system.

Main Methods:

• Diagnosis relies on clinical signs, elevated B-type natriuretic peptide, preserved ejection fraction, and echocardiographic evidence of diastolic dysfunction.
• Analysis of patient data reveals increased left ventricular mass and hypertension history in ~80% of diastolic HF patients.
• Review of studies implicating renin-angiotensin-aldosterone system activation in diastolic dysfunction pathogenesis.

Main Results:

• Diastolic HF is highly prevalent, especially in elderly populations.
• Hypertension and increased left ventricular mass are common comorbidities.
• Neurohormonal activation, particularly the renin-angiotensin-aldosterone system, is central to the condition's progression.

Conclusions:

• Diastolic HF is a significant clinical problem with high mortality.
• Understanding the role of the renin-angiotensin-aldosterone system is crucial for treatment.
• Agents antagonizing this system offer a potential therapeutic strategy for diastolic dysfunction.